Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-337-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: other routes
Administrative data
- Endpoint:
- short-term repeated dose toxicity: other route
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 15 June 1989 - 20 September 1989
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study was conducted under GLP conditions, but not according to an OECD guideline. However, the study design is proper and comparable to that of other scientific subacute studies (only alternative route of exposure). The results are reported extensively.
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- CR733S was administered by IP injection at a dose level of 0, 0.000175, 0.00175, 0.5, 50 or 500 mg/kg bw/day for at least 28 days. 50 mg/kg bw/day Triphenyl phosphate (TPPA) was used as comparative control. Animals were observed twice daily for signs of toxicity or mortality. Body weight and food consumption were assessed. Urine and blood samples were collected for evaluation of hematology, clinical chemistry and cholinesterase activity prior to necropsy and postmortem examinations.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 3-[(diphenoxyphosphoryl)oxy]phenyl diphenyl phosphate
- EC Number:
- 701-337-2
- Cas Number:
- not available
- Molecular formula:
- C30H24O8P2
- IUPAC Name:
- 3-[(diphenoxyphosphoryl)oxy]phenyl diphenyl phosphate
- Details on test material:
- - Name of test material (as cited in study report): CR733S
- Physical state: Liquid
- Lot/batch No.: Confidential information
- Storage condition of test material: At room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- corn oil
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 0.000175, 0.00175, 0.5, 50 or 500 mg/kg bw/day
- No. of animals per sex per dose:
- 12
- Control animals:
- yes, concurrent vehicle
- other: comparative control: 50 mg/kg bw/day triphenyl phosphate (TPPA)
Results and discussion
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 0.5 mg/kg bw/day
- Sex:
- male/female
- Basis for effect level:
- other: Decreased plasma cholinesterase in females; inhibition of esterase activity in males and females
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
- No mortality
- No adverse clinical signs (indicating that blood-brain barrier cannot be penetrated to cause CNS response)
- No effect on body weight, food consumption, whole blood or erythrocyte cholinesterase, hematology or serum chemistry parameters or urinanalysis
- Significant decrease in plasma cholinesterase for both sexes of 500 mg/kg bw/day group and females of 50 mg/kg bw/day and TPPA control group
- Significant increase in relative liver weight for both sexes in the 500 mg/kg bw/day group and TPPA control group
- Non-specific esterase stains of liver imprints showed clear presence of esterase inhibition in 50 and 500 mg/kg bw/day groups and TPPA control group
- Histopathology: Local irritation of mesentery and adjacent adipose tissue or on the serosal surface of some visceral organs in 500 mg/kg bw/day group: slight to moderate fat necrosis and granulomatous inflammatory response (with increased number of lymphoid cells and macrophages as compared to controls; also presence of numerous multinucleated phagocytic giant cells)
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of this study, the dose level of 500 mg/kg bw/day caused significant adverse effects (decrease in plasma cholinesterase, increase of relative liver weight, inhibition of esterase activity and histopathological effects). At 50 mg/kg bw/day inhibition of esterase activity was observed (both male and female), as well as decreased plasma cholinesterase levels in females. The comparative control group (TPPA) showed a decrease in plasma cholinesterase, increase of liver weight and inhibition of esterase activity. Based on the observed resultsNOAEL of 0.5 mg/kg bw/day.
- Executive summary:
CR733S was administered by IP injection at a dose level of 0, 0.000175, 0.00175, 0.5, 50 or 500 mg/kg bw/day for at least 28 days. 50 mg/kg bw/day Triphenyl phosphate (TPPA) was used as comparative control. Animals observed twice daily for signs of toxicity or mortality. Body weight and food consumption were assessed. Urine and blood samples were collected for evaluation of hematology, clinical chemistry and cholinesterase activity prior to necropsy and postmortem examinations.
No mortality and adverse clinical signs were observed in any group. No effect on body weight, food consumption, whole blood or erythrocyte cholinesterase, hematology or serum chemistry parameters or urinanalysis. A significant decrease in plasma cholinesterase for both sexes of 500 mg/kg bw/day group and females of 50 mg/kg bw/day and TPPA control group was noted. Additionally, a significant increase in relative liver weight for both sexes in the 500 mg/kg bw/day group and TPPA control group was observed. Inhibition of esterase was clearly present in non-specific esterase stains of liver imprints in the 50 and 500 mg/kg bw/day groups and TPPA control group. Local irritation of mesentery and adjacent adipose tissue or on the serosal surface of some visceral organs in 500 mg/kg bw/day group: slight to moderate fat necrosis and granulomatous inflammatory response. This was accompanied with increased number of lymphoid cells and macrophages as compared to controls and also the presence of numerous multinucleated phagocytic giant cells.
Under the conditions of this study, the dose level of 500 mg/kg bw/day caused significant adverse effects (decrease in plasma cholinesterase, increase of relative liver weight and histopathological effects). At 50 mg/kg bw/day decrease in plasma cholinesterase in females was observed, and clear inhibition of esterase activity in both males and females. A NOAEL of 0.5 mg/kg bw/day could be established based on these results.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.